April 1, 2022 5:17pm

New month and quarter with the oversold cell and gene therapy sector jumping into positive territory

Pre-open indications: 6 Hits and 3 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

The week in review … The metrics say it all … just the facts

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +139.92 points (+0.40%); the S&P closed UP +15.45 points (+0.34%) while the Nasdaq closed UP +40.98 points (+0.29%)

 

Henry’omics:

Indexes closed up on Friday as investors kicked off the 1st trading day of Q2.

With U.S. economic growth so robust and inflation running at three times the Federal Reserve's 2% target, investors are widely expecting a drum roll of interest rate rises this year. <Reuters>

The market and closed off its 1st negative quarter in two (2) years, but there were positive signs for the cell and gene therapy sector investors on Friday.

Volume was mixed, rising on the New York Stock Exchange but slipped slightly on the Nasdaq.

Economic Date Docket: Employers added 431,000 jobs in March, below Bloomberg consensus economist estimates of a 490,000 rise in non-farm payrolls.

  • Unemployment data reflected a slowdown from February's 678,000 gain but still marked an increase well above pre-pandemic trends.
  • Bottom line, the jobs data still came in weaker than expected.
  • Be ready as interest rates jump higher and economic growth slows.
  • There were some more negative economic readings on Friday, with February construction spending data and March manufacturing data from ISM coming in below expectations.

For the week, the S&P 500 squeaked out a slight gain while the Dow declined 0.12% and the Nasdaq added 0.65%.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday opened positive at 28 up/5 downs, 2 flats, stayed positive at the mid-day at 25/8 and 2 flats, ending with a positive close of 27/6 and 2 flats;
  • Thursday opened positive at 23 up/10 downs, 2 flats, flipped negative at the mid-day at 13/31 and 1 flat, ending with a negative close of 9/24 and 2 flats;
  • Wednesday opened negative at 16 up/17 downs, 2 flats, flipped positive at the mid-day at 18/16 and 1 flat, ending with a negative close of 7/28;
  • Tuesday opened positive at 32 up/2 downs, 1 flat, stayed positive at the mid-day at 32/2 and 1 flat, ending with a positive close of 7/28;
  • Monday opened negative at 28 up/5 downs, 2 flats, stayed negative at the mid-day at 6/29 and 0 flat, ending with a negative close of 13/20 and 2 flats;

 

Pre-open Indications: 6 Hits < Biostage (BSTG flat at $0.00 with 10 shares traded after Thursday’s -$0.10 with 124 shares traded, Wednesday’s +$0.50 with 3,926 shares traded, Tuesday’s -$0.50 with 3,300 shares traded), Agenus (AGEN +$0.11), Beam Therapeutics (BEAM +$1.65), CRISPR Therapeutics (CRSP +$3.38), Sage Therapeutics (SAGE +$3.90), Caribou Biosciences (CRBU +$0.04), > 3 Miss < Global Blood Therapeutics (GBT +$1.27), Fate Therapeutics (FATE +$2.55), Ionis Pharmaceuticals (IONS +$1.86)     

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (VSTM, BCLI, ADVM & BSTG) added with 34 to date

 

Key Metrics:

  • Friday - Sector volume was LOW with 8 of the 27-upside having higher than the 3-month average volume with LOW volume of 1 of 6-downside having higher than the 3-month average volume;
  • Thursday - Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with LOW volume of 3 of 24-downside having higher than the 3-month average volume;
  • Wednesday - Sector volume was LOW with 3 of the 7-upside having higher than the 3-month average volume with LOW volume of 3 of 28-downside having higher than the 3-month average volume;
  • Tuesday - Sector volume was LOW with 8 of the 32-upside having higher than the 3-month average volume with LOW volume of 3 of 3-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 2 of the 13-upside having higher than the 3-month average volume with LOW volume of 4 of 20-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was up +2.12% and the XBI was up +3.76%
  • Thursday, the IBB was down -0.51% and the XBI was down -0.88%
  • Wednesday, the IBB was down -1.31% and the XBI was down -3.07%
  • Tuesday, the IBB was up +2.82% and the XBI was up +4.28%
  • Monday, the IBB was up +0.71% and the XBI was up +0.10%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.93 points or -4.52% at 19.63
  • Thursday was up +1.23 points or +6.36% at 20.56
  • Wednesday was up +0.40 points or +2.12% at 19.30
  • Tuesday was down -0.73 points or -3.72% at 18.90
  • Monday was down -1.18 points or -5.67% at 19.63

 

Jumping with share pricing momentum (10 of 27):

  • Alnylam Pharmaceuticals (ALNY +$6.00 after Thursday’s -$1.95, Wednesday’s -$1.50, Tuesday’s +$5.09 and Monday’s -$2,16),
  • Ultragenyx (RARE +$4.75 after Thursday’s +$1.26, Wednesday’s +$0.25, Tuesday’s -$0.90 and Monday’s -$0.97),
  • Sage Therapeutics (SAGE +$3.90 after Thursday’s -$1.18, Wednesday’s -$1.02, Tuesday’s +$1.59 and Monday’s +$1.29),
  • Intellia Therapeutics (NTLA +$3.46 after Thursday’s +$0.49, Wednesday’s -$4.05, Tuesday’s +$3.15 and Monday’s +$2.43),
  • CRISPR Therapeutics (CRSP +$3.38 after Thursday’s -$1.31, Wednesday’s -$1.87, Tuesday’s +$3.12 and Monday’s +$0.69),
  • Beam Therapeutics (BEAM +$2.65 after Thursday’s -$2.15, Wednesday’s -$2.58, Tuesday’s +$2.97 and Monday’s +$1.03),
  • Fate Therapeutics (FATE +$2.55 after Thursday’s -$1.09, Wednesday’s -$2.08 and Tuesday’s +$3.94),
  • Ionis Therapeutics (IONS +$1.86 after Thursday’s +$1.35 after Wednesday’s -$0.79),
  • Regenxbio (RGNX +$1.84 after Thursday’s +$0.14),
  • uniQure NV (QURE +$1.38 after Thursday’s +$0.19),

Hammered in today’s market (6 of 6):

  • AVROBIO (AVRO -$0.07),
  • Pluristem (PSTI -$0.07),
  • Homology Medicine (FIXX -$0.06 after Thursday’s +40.02),
  • Bellicum Pharmaceuticals (BLCM-$0.04 after Thursday’s +$0.23),
  • Adverum Biotechnologies (ADVM -$0.01),

Closing FLAT:

  • Biostage (BSTG) and Applied Genetic Technologies (AGTC)

 

April, Q2/2022:

  • Friday closed positive with 27 incliners and 6 decliners and 2 flats

 

The BOTTOM LINE: New month and quarter and hopefully new trading patterns evolve.

Funny how little positive news has been generated to fill the “bellies of funds”.

Although, the relative strength line seems to be moving higher following recent pullbacks and has been making general progress.

Be aware, “An inversion of the yield curve, when shorter-dated yields rise above longer-dated ones, is seen as a harbinger of a recession in the next one or two years.”

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.